Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing.

CONCLUSION: In this population-based study we could confirm the previously described increased incidence of PCNSL. The prognosis remains poor despite the inclusion of treatment with rituximab during the study period. A high proportion of the patients had a history of an autoimmune or inflammatory disease not previously described but there was no increase during the study period. PMID: 28084866 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28084866?dopt=Abstract

Source: Acta Oncologica - January 12, 2017 Category: Cancer & Oncology Authors: Enblad G, Martinsson G, Baecklund E, Hesselager G, Sundström C, Amini RM, Hagberg H Tags: Acta Oncol Source Type: research